A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Induction Chemotherapy for Newly Diagnosed Fit Adults With Acute Myeloid Leukemia
Latest Information Update: 20 Mar 2024
At a glance
- Drugs Azacitidine (Primary) ; Venetoclax (Primary) ; Cytarabine; Cytarabine/daunorubicin; Daunorubicin; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 21 Jan 2022 Planned End Date changed from 30 Jun 2023 to 1 Jan 2026.
- 21 Jan 2022 Planned primary completion date changed from 31 Jan 2022 to 1 Jan 2025.
- 21 Jun 2021 Status changed from not yet recruiting to recruiting.